PI3K/mTOR dual inhibitors (Pfizer)

N/A

Report date: 2025/03/20 20:00:06
NME

Base Information

Drug NamePI3K/mTOR dual inhibitors (Pfizer)
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPI3-kinase class I inhibitorsSerine/threonine-protein kinase mTOR inhibitors
TargetsSerine/threonine-protein kinase mTORPI3-kinase class I
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesPfizer Inc
Active IndicationsN/A
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A